Description

CJC-1295 No DAC / Ipamorelin Blend 10 mg

CJC-1295 No DAC / Ipamorelin is a research peptide blend containing 5 mg CJC-1295 No DAC (Modified GRF 1-29) and 5 mg Ipamorelin, providing a total peptide quantity of 10 mg.

The two peptides are studied experimentally in relation to distinct but associated endocrine signalling pathways. CJC-1295 No DAC is a growth hormone-releasing hormone (GHRH) analogue, while Ipamorelin demonstrates activity at the growth hormone secretagogue receptor (GHS-R1a).

Benchmark Peptides supplies this peptide blend as a research material for laboratory and analytical use only. This product is not supplied or intended for human or veterinary use.

Product Specifications

• Product: CJC-1295 No DAC / Ipamorelin Blend
• Catalogue Reference: CJCIPA10
• Composition: 5 mg CJC-1295 No DAC + 5 mg Ipamorelin
• Total Quantity: 10 mg
• Physical Form: Lyophilised material
• Appearance: White to off-white
• Grade: Research grade
• Batch: See current batch information
• Analytical Documentation: See current Certificate of Analysis

Research Information

This blend combines two synthetic peptides investigated in relation to growth hormone-associated endocrine signalling.

CJC-1295 No DAC / Modified GRF (1-29)

CJC-1295 No DAC, also referred to as Modified GRF (1-29), is a synthetic analogue of growth hormone-releasing hormone (GHRH). It is studied experimentally in relation to GHRH receptor activity and associated endocrine signalling pathways.

Ipamorelin

Ipamorelin is a synthetic pentapeptide characterised by activity at the growth hormone secretagogue receptor (GHS-R1a), also known as the ghrelin receptor.

Scientific research involving these peptides and their associated pathways includes investigation of:

• GHRH receptor signalling
• GHS-R1a receptor signalling
• Growth hormone-associated pathways
• GH/IGF-1 axis physiology
• Pituitary signalling mechanisms
• Endocrine peptide-receptor interactions
• Growth hormone secretory patterns

The combination provides a laboratory model for investigating two distinct receptor pathways associated with growth hormone regulation.

Information provided by Benchmark Peptides is intended solely to identify and characterise the research materials supplied. It should not be interpreted as medical information, treatment guidance or a recommendation for use.

Batch & Quality Information

Batch-specific analytical information is provided through the Certificate of Analysis available for this product.

Where available, the Certificate of Analysis provides information including:

• Batch identification
• Analytical identity
• Analytical purity
• Testing methodology
• Laboratory information
• Test date and associated analytical data

For peptide blends, analytical documentation should be reviewed with consideration of both components of the supplied material.

Analytical results relate specifically to the identified batch and should not be interpreted as establishing suitability for any particular application.

Storage & Laboratory Handling

Store the sealed research material according to the conditions specified in the applicable product or batch documentation.

For longer-term laboratory storage, protect the material from excessive heat, moisture and direct light.

Where the material is prepared in solution for legitimate analytical or laboratory work, appropriate preparation, handling and storage conditions should be determined by the researcher’s validated laboratory protocol.

Package Contents

• 1 × CJC-1295 No DAC / Ipamorelin research vial
• 5 mg CJC-1295 No DAC + 5 mg Ipamorelin
• 10 mg total peptide content
• Tamper-evident closure
• Batch identification

Product Category

Growth Hormone Research

This material is categorised according to its use in experimental research involving GHRH, GHS-R1a and growth hormone-associated endocrine signalling pathways.

Important Notice

FOR RESEARCH USE ONLY

Supplied exclusively as a laboratory research material.

NOT FOR HUMAN OR VETERINARY USE.

Not supplied for administration, diagnosis, treatment, cure or prevention of any disease.

Researchers are responsible for ensuring that acquisition, possession, handling and use comply with all applicable laws, regulations and institutional requirements.